- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
John Theurer Cancer Center, Hackensack University Medical Center | Strategic Alliance Partners
ABOUT HACKENSACK UNIVERSITY MEDICAL CENTER
Hackensack University Medical Center, a 803-bed nonprofit teaching and research hospital, was Bergen County’s first hospital founded in 1888. It was also the first hospital in New Jersey and second in the nation to become a Magnet®-recognized hospital for nursing excellence, receiving its sixth consecutive designation from the American Nurses Credentialing Center. The academic flagship of the Hackensack Meridian Health network, Hackensack University Medical Center is Nationally-Ranked by U.S. News & World Report 2022-2023 in four specialties, more than any other hospital in New Jersey. The hospital is home to the state's only nationally-ranked Urology and Neurology & Neurosurgery programs, as well as the best Cardiology & Heart Surgery program. It also offers patients nationally-ranked Orthopedic care and one of the state’s premier Cancer Centers (John Theurer Cancer Center at Hackensack University Medical Center). Hackensack University Medical Center also ranked as High-Performing in conditions such as Acute Kidney Failure, Heart Attack (AMI), Heart Failure, Pneumonia, chronic obstructive pulmonary disease (COPD), Diabetes and Stroke. As well as High Performing in procedures like Aortic Valve Surgery, Heart Bypass Surgery (CABG), Colon Cancer Surgery, Lung Cancer Surgery, Prostate Cancer Surgery, Hip Replacement and Knee Replacement. Named to Newsweek’s World’s Best Hospitals 2023 list, Hackensack University Medical Center is also the recipient of the 2023 Patient Safety Excellence Award™ by Healthgrades as well as an “A” Hospital Safety Grade from The Leapfrog Group. This award-winning care is provided on a campus that is home to facilities such as the Heart & Vascular Hospital; and the Sarkis and Siran Gabrellian Women’s and Children’s Pavilion, which houses the Donna A. Sanzari Women’s Hospital and the Joseph M. Sanzari Children’s Hospital, ranked #1 in the state and top 20 in the Mid-Atlantic Region in the U.S. News & World Report’s 2022-23 Best Children’s Hospital Report. Additionally, the children’s nephrology program ranks in the top 50 in the United States. Hackensack University Medical Center is also home to the Deirdre Imus Environmental Health Center and is listed on the Green Guide’s list of Top 10 Green Hospitals in the U.S. Our comprehensive clinical research portfolio includes studies focused on precision medicine, translational medicine, immunotherapy, cell therapy, and vaccine development. The hospital has embarked on the largest healthcare expansion project ever approved by the state: Construction of the Helena Theurer Pavilion, a 530,000-sq.-ft., nine-story building, which began in 2019. A $714.2 million endeavor, the pavilion is one the largest healthcare capital projects in New Jersey and will house 24 state-of-the-art operating rooms with intraoperative MRI capability, 50 ICU beds, and 175 medical/surgical beds including a 50 room Musculoskeletal Institute.
Latest from John Theurer Cancer Center, Hackensack University Medical Center
Dr. Goy on Bendamustine Plus Cytarabine as MCL Treatment
March 21, 2017
Video
Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the efficacy of bendamustine plus cytarabine as treatment for patients with mantle cell lymphoma.
Dr. Goy on BR Plus Bortezomib for MCL Treatment
March 15, 2017
Video
Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the combination of bendamustine and rituximab (Rituxan; BR) plus bortezomib (Velcade) as a potential treatment for patients with mantle cell lymphoma (MCL).
Dr. Goy on Advancements in Relapsed/Refractory Mantle Cell Lymphoma
March 06, 2017
Video
Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses recent therapeutic advancements in the field of mantle cell lymphoma (MCL).
Dr. Goy on Maintenance Strategies in MCL Treatment
February 28, 2017
Video
Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses maintenance strategies for treating patients with mantle cell lymphoma.
Dr. Goy on Efficacy With Ibrutinib in MCL
February 22, 2017
Video
Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the efficacy reported with ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL).
Dr. Goy on Impact of Lenalidomide on MCL Treatment
February 09, 2017
Video
Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the impact lenalidomide (Revlimid) has had on the treatment paradigm of mantle cell lymphoma (MCL).
Dr. Goy on Takeaways in Mantle Cell Lymphoma for the Future
February 04, 2017
Video
Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the takeaways for community oncologists in the field of mantle cell lymphoma (MCL).
Dr. Goy on the Role of Immunotherapy in Mantle Cell Lymphoma
February 01, 2017
Video
Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses immunotherapy agents currently being evaluated in the treatment of patients with mantle cell lymphoma.
Dr. Goy on Approved Agents in the Treatment Landcsape of MCL
January 26, 2017
Video
Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses novel agents approved for the treatment of patients with mantle cell lymphoma.
Dr. Goy on Bortezomib in MCL Treatment
December 30, 2016
Video
Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the history of bortezomib as a treatment for patients with mantle cell lymphoma.
Dr. Goy on Rituximab Maintenance Therapy for Patients With MCL
December 21, 2016
Video
Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses phase III results of a study exploring rituximab as maintenance therapy after autologous stem cell transplantation in younger patients with mantle cell lymphoma.
New Options Emerge in Frontline, Adjuvant RCC Care
November 17, 2016
Article
Therapeutic options for patients with renal cell carcinoma have increased rapidly in the past decade, yet the field is still poised to expand significantly in the coming years, said Robert S. Alter, MD.
John Theurer Cancer Center Launches Podcast Series
February 26, 2016
Article
The John Theurer Cancer Center (JTCC) at Hackensack University Medical Center today announced the launch of "JTCC: The Future of Cancer Care," a podcast series featuring in-depth conversations with clinicians and researchers.
Pacritinib May Offer New Option for Tackling Myelofibrosis in Patients With Cytopenias
February 03, 2016
Article
Pacritinib, a JAK2/FLT3 inhibitor, is among the most promising of those emerging options for patients with myelofibrosis.
Allogeneic CAR T-Cell Therapy Shows Promising Efficacy Without GVHD
January 29, 2016
Article
Treatment with allogeneic anti–CD19 chimeric antigen receptor–modified T cell therapy induced complete remissions in 30% of patients with advanced progressive B-cell malignancies without causing graft-versus-host disease.
Goy on Going Beyond R-CHOP in Large-Cell Lymphoma
November 19, 2015
Article
Dr. Andre Goy discusses combining novel agents with R-CHOP for the treatment of large-cell lymphoma.
Clinical Trials: The Elephant in the Room
November 15, 2015
Article
Failed clinical trials come at a huge cost to pharmaceutical sponsors, patients' lives, and society through impact on innovation.
Precision Medicine Carries Significant Challenges but Will (Eventually) Lower Cancer Care Costs and Is the Way to Go (Precisely)
October 19, 2015
Article
Our goal should be to use precision medicine as a way to deliver value-based care.
DNA Damage Response: A Constant Effort to Maintain Cell Integrity Might Help Cancer Patients After All
September 22, 2015
Article
The continued progress in understanding and deciphering the critical role of the DNA damage response might help us stratify cancer patients in the future and personalize their therapies.
Lack of Drug Information Makes it Hard to Get Payer Approvals
August 20, 2015
Article
Data collection has to be improved in order for physicians to be able to convince payers to support certain types of costly therapy, a panel of physicians.